KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Association between screening duration and treatment outcomes in the clinical trials of ranibizumab and aflibercept for neovascular age-related macular degeneration.

Hyeong Min Kim, Se Joon Woo

Sci Rep 16(1) 15680

PMID41927600
PMCIDPMC13187178
DOI10.1038/s41598-026-41200-3
发表日期2026-04-02
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:森林图/亚组分析图。
摘要

摘要

The clinical implications of screening duration prior to treatment initiation in neovascular age-related macular degeneration (nAMD) are not well understood. This post hoc analysis investigated whether screening duration influences treatment outcomes in two multinational phase 3 randomized clinical trials, SB11 (ranibizumab biosimilar) and SB15 (aflibercept biosimilar), comprising a total of 1,152 participants (704 from the SB11 trial and 448 from the SB15 trial) with nAMD. Screening duration was assessed in relation to changes in best-corrected visual acuity (BCVA) and central subfield thickness (CST) at weeks 8 and 48. Multiple linear and logistic regression analyses, adjusted for age and baseline BCVA/CST, showed no significant associations between screening duration and either visual or anatomical outcomes at both time points. Linear regression coefficients for screening duration were not statistically significant for BCVA or CST at week 8 (BCVA: B = - 0.058, P = 0.242; CST: B = - 0.050, P = 0.908) or at week 48 (BCVA: B = - 0.015, P = 0.843; CST: B = 0.036, P = 0.930). These findings suggest that a screening period of up to 21 days does not adversely affect treatment efficacy in clinical trial settings and support the clinical feasibility of short pre-treatment delays.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Trend analyses of best corrected visual acuity (BCVA) and central subfield thickness (CST) were conducted according to screening duration from day 1 to day 21. ( A , D ) Baseline BCVA/CST, ( B , E ) Week 8 BCVA/CST changes, and ( C , F ) Week 48 BCVA/CST changes were plotted. Each participant is represented as a dot, with red dots for SB11 participants and blue dots for SB15 participants.
非 KM Figure
Fig. 2Fig. 2 Logistic regression analyses to assess treatment success, defined as an improvement of ≥ 5 ETDRS letter scores in BCVA and a reduction of ≥ 100 μm in CST. ( A , C ) Week 8 BCVA/CST changes and ( B , D ) Week 48 BCVA/CST changes. In each set of paired figures, the left one corresponds to SB11 and the right one to SB15. The gray zone and line indicate the odds ratios and probability according to screening time duration day 1 to day 21.
非 KM Figure
Fig. 3Fig. 3 Subgroup analyses for ( A ) BCVA and ( B ) CST changes according to screening duration: day 1–5 (red line), day 6–10 (green line), day 11–15 (blue line), and day 16–21 (purple line).
非 KM Figure